Monitors blood markers after surgery for colorectal or stomach cancer
Tests whether tracking blood markers helps spot complications early in adults after cancer surgery.
Plain-language title generated from the registry record
Registry title: Perioperative Biomarkers in Colorectal and Gastric Cancer Surgery
Key facts
- Where
- Bucharest, RomaniaSee the site
Where in Romania
- Emergency Clinical Hospital BucharestBucharest, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bucharest Emergency Hospital
- Trial code
- NCT07881133
- Record updated
- 19 October 2026
- Original description
This study aims to evaluate whether monitoring perioperative inflammatory and metabolic biomarkers can help identify postoperative complications early in adult patients undergoing colorectal or gastric cancer surgery.Read full original descriptionShow less
Temporal Profiles of Inflammatory Markers in General Oncologic Surgery
This study aims to evaluate whether monitoring perioperative inflammatory and metabolic biomarkers can help identify postoperative complications early in adult patients undergoing colorectal or gastric cancer surgery.
The study is a randomized controlled trial conducted at Bucharest Emergency Clinical Hospital, Romania. Participants are assigned to either an intervention group receiving enhanced recovery care (ERAS) combined with perioperative biomarker monitoring or a control group receiving standard postoperative care.
The biomarkers of interest include procalcitonin, lactate, and blood glucose. The study will examine their relationship with postoperative complications, particularly infections and anastomotic leakage.
Participants will be followed for 30 days after surgery to assess postoperative complications, hospital length of stay, readmissions, and mortality.
The findings may help improve postoperative monitoring and support earlier recognition of complications in patients undergoing cancer surgery.
Inclusion: Adult patients aged 18 years or older; Patients diagnosed with colorectal or gastric cancer; Patients scheduled for elective abdominal oncologic surgery; Patients classified as ASA physical status II-IV; Patients who provide written informed consent to participate in the study.
Exclusion: Patients with known autoimmune or immunological diseases that may significantly influence inflammatory biomarker levels; Patients diagnosed with inflammatory bowel disease (IBD); Patients who refuse to participate or do not provide written informed consent.